Tiziana Life Sciences Ltd TLSA
0.65 USD +0.07 (+12.46%)
Regular-session close
0.69 +0.04 +6.48%
After hours · Nov 17, 5:59 PM ET
0.58 Day range 0.75
0.55 52-week range 1.90
- YTD
- -56.51%
- 1 year
- -61.66%
News
seekingalpha.com Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Secondary Progressive Multiple Sclerosis Transcript Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Secondary Progressive Multiple Sclerosis Transcriptbenzinga.com Tiziana Life Sciences Highlights Phase 2a INFORM-MS Success For Intranasal Foralumab, Showing Reduced Neuroinflammation And Improved Fatigue In Secondary Progressive MS Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
globenewswire.com Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
globenewswire.com Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
reuters.com Tiziana's experimental MS treatment meets main goals in mid-stage study Tiziana's experimental MS treatment meets main goals in mid-stage studybenzinga.com Tiziana Life Sciences Announces Topline Data In Phase 2a INFORM-MS Trial With Intranasal Foralumab In Patients With Na-SPMS; Trial Meets Dual Primary Endpoints Trial met its dual primary endpoints for (1) statistically significant reduction (p=0.0168) in microglial activation as measured by TSPO PET imaging in patients treated with 50 ug nasal foralumab as…
globenewswire.com Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
proactiveinvestors.com Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient has begun dosing in its Phase 2 trial of intranasal foralumab in early or mild Alzheimer's disease, with topline data expected in the…
globenewswire.com Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
proactiveinvestors.com Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy Tiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the US Food and Drug Administration to grant orphan drug designation to its intranasal foralumab for multiple system atrophy (MSA), a rare…
proactiveinvestors.com Tiziana doses first three patients in ALS trial of nasal antibody foralumab Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the first three participants have received their first dose of intranasal foralumab in a Phase 2a trial in people living with amyotrophic lateral…
proactiveinvestors.com Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Monday the last patient has completed their final visit in the company's Phase 2a clinical trial evaluating intranasal foralumab in patients with…
proactiveinvestors.com Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial Tiziana Life Sciences Ltd (NASDAQ:TLSA) has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases to…
proactiveinvestors.com Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a…
proactiveinvestors.com Dow climbs as stocks rebound on earnings, falling Treasury yields 3:40pm: Small cap wrap Tiziana Life Sciences Ltd (NASDAQ:TLSA) received a Buy rating and $7 price target from BTIG, which highlighted its nasal anti-CD3...
proactiveinvestors.com Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026 Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday. The…
globenewswire.com Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
proactiveinvestors.com Gemini Pro delay leaves Google with an empty flagship tier Polymarket, the crypto-based prediction platform, puts the probability of no new Gemini Pro release before 30 September at 69%. Every specific launch date...
proactiveinvestors.com Tiziana Life Sciences announces CEO share purchase Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its CEO Ivor Elrifi increased his stake in the company through the purchase of 321,423 common shares on Nasdaq...
globenewswire.com Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
benzinga.com Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition Biotechnology firm Tiziana Life Sciences Ltd. (NASDAQ:TLSA) on Friday revealed promising quantitative PET imaging results from the third patient participating in its Phase 2 clinical trial.
proactiveinvestors.com Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal…
